Latest Breaking News On - Abfero pharmaceuticals - Page 1 : vimarsana.com

Possible Polymer Delivery Systems Outnumber the Stars

Possible Polymer Delivery Systems Outnumber the Stars
genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.

United statesSean kevlahanThomas neenanShashi murthyCystic fibrosis foundationAbfero pharmaceuticalsResearch foundationQuad technologiesCharcot marie tooth research foundation

Iron Overload Syndrome Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Space

Iron Overload Syndrome Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Space
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.

United kingdomKritika rehaniDelveinsight intrahepatic cholangiocarcinomaDelveinsight sarcopeniaExjade deferasiroxMarket researchNovartis pharmaceuticalsResearch newswireSee campaignKey companiesProtagonist therapeutics incAbfero pharmaceuticalsIron overload syndrome market insights reportIron overload syndromeIron overload syndrome market insightsProtagonist therapeutics

AbFero Pharmaceuticals Announces Initiation Of Phase 1 Study For Lead Iron Chelator

AbFero Pharmaceuticals Announces Initiation Of Phase 1 Study For Lead Iron Chelator Study to Examine Safety of SP-420 in MDS and MF News provided by Share this article Share this article BOSTON, Feb. 23, 2021 /PRNewswire/ AbFero Pharmaceuticals, Inc., a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, today announced the initiation of a Phase 1 study of its lead iron chelator, SP-420, in myelodysplastic (MDS) and myelofibrosis patients (MF) with transfusional iron overload (TIO). The opening of this trial in MDS and MF marks another critical step forward on the development path for SP-420, said AbFero CEO Thomas X. Neenan. Following the recently awarded Parkinson s research grants from EUREKA Eurostars and Cure Parkinson s, this trial is an additional building block in our strategy of developing safe chelators for both hematological indications and diseases of aging where iron is implicated.

United statesUnited kingdomRuben mesaElizabeth bowhay carnesThomasx neenanRaymond bergeronMays cancer centerMalignant hematology programUt health san antonioUniversity of floridaAbfero pharmaceuticals incAbfero ltdAbfero pharmaceuticalsCure parkinsonTexas health science center sanAdult non malignant hematology program

AbFero Pharmaceuticals Announces Funding From Cure Parkinson s For Lead Compound SP-420

AbFero Pharmaceuticals Announces Funding From Cure Parkinson s For Lead Compound SP-420 Second Parkinson s Grant to Clinical Stage Pharmaceutical Company Developing Iron Chelators HARWELL, England, Feb. 17, 2021 /PRNewswire/ AbFero Ltd., a subsidiary of AbFero Pharmaceuticals, Inc., a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, today announced the award of a grant from Cure Parkinson s for the development of their lead, brain-penetrant iron chelating agent, SP-420, as a disease modifying therapy for Parkinson s disease (PD). The funding will be used to develop biomarkers to demonstrate that SP-420 is an effective targeted therapy for Parkinson s. This is the second grant AbFero has received to support development of SP-420 for the condition, following recent funding from Eureka EUROSTARS.

United kingdomKostenloser wertpapierhandelThomas neenanRichard wyseDavid devosRaymond bergeronUniversity of lilleResearch development at cure parkinsonUniversity of floridaAbfero pharmaceuticals incPrnewswire abfero ltdAbfero ltdSecond parkinsonFero ltdAbfero pharmaceuticalsCure parkinson